MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Monday, October 19, 2015

Teva Pharmaceutical Industries’ COPAXONE 40 mg/mL Three-times-a-week Approved in Russia for Relapsing-Remitting Multiple Sclerosis

Russian Ministry of Health approves Teva's COPAXONE new formulation for the treatment of RRMS<span class="entry-title">Teva Pharmaceutical Industries’ COPAXONE 40 mg/mL Three-times-a-week Approved in Russia for Relapsing-Remitting Multiple Sclerosis</span><span class="entry-subtitle">Russian Ministry of Health approves Teva's COPAXONE new formulation for the treatment of RRMS</span>

Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day, recently announced the approval of a Marketing Authorization license (MA) by the Russian Ministry of Health for three-times-per-week COPAXONE®(glatiramer acetate injection) 40 mg/mL, a new dose of COPAXONE®, to treat patients with a diagnosis of relapsing-remitting multiple sclerosis (RRMS). This new COPAXONE® formulation will reduce the frequency of dose regimen for RRMS patients in Russia.
“For more than 20 years, Teva has been committed to safe and tolerable treatments options for patients with multiple sclerosis. The availability of three-times-a-week COPAXONE® 40 mg/mL is a significant advancement for the multiple sclerosis patient community in Russia,”said Rob Koremans, MD, President and CEO of Global Specialty Medicines at Teva in a pressrelease. “The new three-times-a-week COPAXONE® 40 mg/mL is the same therapy that patients and physicians know and trust with almost 60 percent fewer injections per year compared to the current daily COPAXONE® 20 mg/mL formulation. In the U.S., for example, more than 70 percent of patients currently receiving glatiramer acetate treatment are receiving the COPAXONE® 40 mg/mL formulation.”

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News helps to provide information for all affected by MS
Keep up to date with the news and information we provide 
by signing up by clicking here
.===================================

No comments: